Compare State Street SPDR S&P Biotech ETF (XBI) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Materials Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $154.37, while Materials Select Sector SPDR Fund trades at $50.64. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| XBI | XLB | |
|---|---|---|
Sector | Broad Market / Factor | — |
52-Week High | $164.28 | $53.62 |
52-Week Low | $85.16 | $42.23 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
XLB trades at $50.03, down 0.99% with a bearish technical signal from moving averages. The materials ETF faces mixed sentiment as recent news highlights sector opportunities from infrastructure trends and geopolitical supply chain shifts, though some analysts caution on valuation after recent gains. Support levels cluster around $49-50 while resistance sits at $51.
Outlook remains cautious with technical weakness offset by structural demand drivers. Key risks include geopolitical sensitivity and cyclical pricing pressure, while potential exists from manufacturing expansion and critical minerals focus. The neutral oscillator readings suggest limited near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
